TargetBeta
C5
complement C5 · also CPAMD4, C5a, C5b · Receptor ligands
8 programs in company-led studies act on C5, from 6 companies: 4 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (7 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| ravulizumabrule | AstraZeneca | phase 4 | 359 running | – | ChEMBL |
| pozelimabrule | Regeneron Pharmaceuticals | phase 4 | 145 running | – | ChEMBL |
| eculizumabrule | AstraZeneca | phase 4 | 381 running | – | ChEMBL |
| Crovalimabrule | Hoffmann-La Roche | phase 3 | 105 running | – | ChEMBL |
| cemdisiranrule | Regeneron Pharmaceuticals | phase 3 | 104 running | – | NCIt |
| zilucoplanrule | UCB | phase 3 | 143 running | – | ChEMBL |
| vilobelimabrule | InflaRx | phase 3 | 132 running | – | NCIt |
| ABBV-6628 | AbbVie | phase 2 | 11 running | – | the company's pipeline |
Conditions their studies are in
- Hemoglobinuria, Paroxysmal, 6 programs
- Myasthenia Gravis, 5 programs
- Atypical Hemolytic Uremic Syndrome, 4 programs
- Geographic Atrophy, 3 programs
- Guillain-Barre Syndrome, 2 programs
- Neuromyelitis Optica, 2 programs
- Anemia, Sickle Cell, 1 program
- Antiphospholipid Syndrome, 1 program
- COVID-19, 1 program
- Glomerulonephritis, IGA, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 7, 2026eculizumab · AstraZeneca · phase 4 · NCT06724809
- Mar 23, 2027zilucoplan · UCB · phase 3 · NCT06961747
- Apr 18, 2027Crovalimab · Hoffmann-La Roche · phase 3 · NCT04432584
- Jun 25, 2027ravulizumab · AstraZeneca · phase 4 · NCT07308574
- Jul 2028vilobelimab · InflaRx · phase 3 · NCT06703073
- Jul 3, 2028pozelimab · Regeneron Pharmaceuticals · phase 4 · NCT07230834
- Jul 31, 2028cemdisiran · Regeneron Pharmaceuticals · phase 3 · NCT06541704
- Oct 2029ABBV-6628 · AbbVie · phase 2 · NCT07160179
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.